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GOSNELL, B. A., M. J. MAJCHRZAK AND D. D. KRAHN. Effects of preferential delta and kappa opioid receptor agonists on 
the intake ofhypotonic saline. PHYSIOL BEHAV 47(3) 601-603, 1990. --A previous study has implicated central mu opioid receptors 
in the preference for salt solutions. Because mu, kappa and delta receptors are all thought to play a role in food intake and/or the 
mediation of palatability, we performed a series of experiments to determine whether preferential agonists at kappa and delta receptors 
might also stimulate the intake of salt solutions. When injected centrally into nondeprived rats, two selective agonists at delta receptors 
caused increases in the intake of 0.6% saline; the intake of concurrently available water was either unchanged or slightly increased. 
The selective kappa agonist U-50,488H had no effect on water or saline intake, whereas the preferential kappa agonist DAFPHEDYN 
caused a delayed increase in saline intake. These results indicate a role for central delta receptors in the preference for salt solutions, 
and are consistent with the suggestion that opioids play a role in the mediation of palatability. 
Opioids Palatability Taste preference Reward Drinking Saline intake 
SEVERAL reports have suggested that endogenous opioids play a 
role in mediating palatibility [see (5,12) for reviews]. Generally, 
opioid antagonists have been found to decrease the preference for 
(or intake of) palatable fluids (3, 5, 8), while opioid agonists 
increase preferences (2,8). Although most studies have dealt with 
the consumption or preferences for sweet-tasting fluids, there are 
indications that these opioid effects can also be obtained with 
nonsweet palatable fluids. Hypo- and isotonic salt solutions are 
preferred over water even in salt-replete rats (10), which suggests 
that these solutions are palatable to rats. Naloxone caused a 
selective reduction in the intake of hypotonic saline solutions (4), 
and reduced 0.9% saline intake at lower doses than those required 
to reduce water intake (11). In water-deprived rats, systemic 
injections of morphine increased rats' preference for isotonic 
saline (1). 
There are at least three types of opioid receptors, the best 
characterized being the mu, kappa and delta (6). Recently, we 
found that a selective mu agonist stimulates the intake of hypo- 
tonic (0.6%) saline in nondeprived rats (9). Because mu, kappa 
and delta receptors are all thought to play a role in food intake 
and/or the mediation of palatability (5, 7-9), we performed a 
series of experiments to determine whether preferential agonists at 
kappa and delta receptors might also stimulate the intake of salt 
solutions. The delta agonists used were [D-Thr 2, LeuS]enkephalin - 
Thr 6 (DTLET) and [D-Pen 2, D-PenS]enkephalin (DPDPE); 
the kappa agonists were U-50,488H and a recently re- 
ported dynorphin analog, [D-Ala 2, (Fs)Phea]-dynorphinl_13-NH2 
(DAFPHEDYN) (13). 
METHOD 
Male Sprague-Dawley rats (Charles River Laboratories, Inc., 
Wilmington, MA) were used in all experiments. At the time of 
surgery, body weights ranged from 239-345 g. They were 
individually housed in stainless steel cages, and food and water 
were available ad lib, except as described below. Lights were on 
for 12 hours daily, and all experiments were carried out in the light 
period. A 20-gauge cannula was implanted into the fight lateral 
ventricle of each rat with techniques similar to those previously 
reported (8,9). Cannula placement was verified by the observation 
of a drinking response to an ICV injection of angiotensin II (AII, 
100 ng). All rats were tested at least once with AII, and all data 
from animals drinking less than 5 ml in 30 min on all tests were 
excluded. Adaptation to testing procedures began no sooner than 3 
days after surgery. 
After an overnight period of water deprivation, rats were 
moved to individual test cages for adaptation to the testing 
procedure. One hour later, a 0.6% sodium chloride (saline) 
solution was presented to each rat in a 25-ml graduated buret fitted 
with a stainless steel sipper tube. After two hr of access to this 
solution, rats were returned to their home cages. After this first 
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FIG. 1. Cumulative intake of water and 0.6% saline following ICV 
injections of the delta agonist DTLET (mean_ + S.E.M.). All rats were 
tested in the nondeprived condition, and each rat was tested with all doses 
(n = 9). Asterisks indicate significant increases above the corresponding 0 
nmol (saline) condition (p<0.05, one-tailed Dunnett's test). 
adaptation session, water was available ad lib in the home cages 
for the remainder of the experiment. Food was available in the 
home cages, but not the test cages. For the next 10-11 days, this 
adaptation procedure was repeated in a similar manner, except that 
two burets were attached to the test cages each day: one contained 
0.6% saline and the other contained water. The positions of the 
two burets were reversed daily. 
The effects of DTLET were tested with a repeated measures 
design. On the first test day, rats were given ICV injections of 0 
(0.9% saline), 1 or 3 nmol of DTLET in a 5 txl volume. 
Injections were given at the time of placement into the test cages, 
and burets were placed on the cages 30 min after injection. This 
delay between injections and fluid access was imposed because, in 
previous studies, we have found that DTLET in this dose range 
produces a cataleptic state which dissipates within 30 min. On test 
days, rats were given 3 hours access to saline and water, after 
which they were returned to their home cages. Saline and water 
intakes were measured every hour. The test procedure was 
repeated two additional times, such that every rat was tested with 
placebo and with both doses of DTLET. Test days were 2-4 days 
apart; on the intervening days, rats were given 2 hr access to water 
and saline without injections. Injection orders for testing the three 
doses were varied across rats, such that every dose was tested in at 
least one rat on each of the three days. For each fluid, Dunnett's 
test (one-tailed) was used at each measurement to compare intake 
in each DTLET condition to the control condition. 
To determine whether DTLET would stimulate water intake 
when saline was not available, rats with previous experience with 
central DTLET injections and with drinking either 0.6% or 1.7% 
saline were tested in a single trial similar to those described above. 
Thirty min after ICV injections of saline (n = 4) or DTLET (3 
nmol, n = 4), a single buret containing water was attached to each 
cage, and intake was measured hourly for 3 hr. 
In three separate groups of rats, the effects of DPDPE [0 
(saline), 15.5 and 46.5 nmol], DAFPHEDYN [0 (water), 1 and 3 
nmol], and U-50,488H [0 (saline), 10 and 30 nmol] were tested 
with procedures similar to those described above, with only a few 
minor exceptions. DAFPHEDYN, DPDPE and U-50,488H rats 
were given 8, 10 and 11 days, respectively, of adaptation to the 
test cages and saline solutions. During adaptation, water and saline 
were presented 60 min (DAFPHEDYN rats), or 15-30 min 
(DPDPE and U-50,488H rats) after placement into the test cages. 
On injection days, DPDPE and U-50,488H rats were transferred to 
the test cages at the time of injection; DAFPHEDYN rats were 
transferred 45 rain before injections. In test of all three agonists, 
burets were placed on the cages 15 min after injections. U- 
50,488H trials were 2 rather than 3 hr in duration. DAFPHEDYN 
was dissolved in HPLC grade water; all other agonists were 
dissolved in saline. DAFPHEDYN was synthesized by Dr. David 
Coy (Tulane University) and was provided by Dr. Hylan Moises 
(University of Michigan). U-50,488H was purchased from the 
Upjohn Co. (Kalamazoo, MI); all other peptides were purchased 
from Sigma Chemical Co. (St. Louis, MO). 
We are not aware of any previous studies on the effects of 
DAFPHEDYN on ingestive behaviors. Therefore, in addition to 
testing its effects on saline intake, we measured the effects of 
similar doses on food intake. A separate group of rats were 
cannulated as described above. In two trials (at least 2 days apart), 
food intake was measured 0.5, 1 and 2 hr after ICV injections of 
DAFPHEDYN (0.5 nmol) and saline. In two additional pairs of 
TABLE 1 
EFFECTS OF THREE OPIOID AGONISTS ON THE INTAKE OF WATER AND 0.6% NaCl 
1 Hr 2 Hr 
Dose 
Agonist (nmol) Water 0.6% NaCI Water 0.6% NaCI 
DPDPE 0 0.4 _ 0.1 2.2 + 0.5 0.5 ~ 0.1 2.4 ± 0.6 
(n=21) 15.5 1.1 - 0.4 *4.7 --- 0.7 "1.2 ± 0.4 *4.8 ± 0.7 
46.5 0.9 ± 0.2 *5.0 ± 0.9 1.0 ± 0.2 *5.3 --- 1.0 
DAFPHEDYN 0 0.6 --- 0.3 2.2 ± 1.0 0.6 ± 0.3 2.2 --+ 1.0 
(n=9) 1 0.1 --- 0.04 2.5 ± 0.6 0.1 --- 0.04 3.3 ± 0.6 
3 0.1 ± 0.1 2.8 --- 1.2 0.3 ± 0.1 "6.1 - 1.6 
U-50,488H 0 0.08 ± 0.05 2.3 ± 0.6 0.1 ± 0.04 2.8 - 0.8 
(n=8) 10 0.08 ± 0.04 1.7 ± 1.1 0.1 ± 0.04 2.2 ± 1.2 
30 0.03 ± 0.02 0.8 -+ 0.5 0.2 --- 0.15 1.3 ± 1.0 
*Significantly different from control (0 nmol); Dunnen's test (one-tailed, p<0.05). 
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trials with the same rats, saline vs. 1 nmol and saline vs. 3 nmol 
were tested. Dunnett's test was used to compare the mean intake 
after each dose of DAFPHEDYN to the mean intake of the pooled 
saline trials. 
RESULTS 
DTLET (1 and 3 nmol) caused selective increases in 0.6% 
saline intake measured at 1, 2 and 3 hours (Fig. 1). Water intake 
was minimal and not affected by DTLET. When only water was 
available, DTLET caused a small but significant increase in 2- and 
3-hr cumulative water intake. DTLET-injected rats drank 1.1 ± 0.5, 
2.1---0.6 and 2.1---0.6 ml at 1, 2 and 3 hr, respectively; 
saline-injected rats consumed only 0.3---0.3 ml in 3 hours. 
DAFPHEDYN (3 nmol) also caused selective increases in cumu- 
lative 0.6% saline intake measured at 2 and 3 hours (Table 1). 
Three-hour results were similar to 2-hour results and are, there- 
fore, not shown. Water intake was minimal (less than 1.0 ml) and 
was not affected by DAFPHEDYN. DPDPE (15.5 and 46.5 nmol) 
caused significant increases in saline intake at each measurement; 
water intake was slightly increased by 1 nmol dose. U-50,488H 
did not significantly affect water or saline intake. 
In the feeding trials with DAFPHEDYN, food intake was 
significantly increased by the 1 nmol dose at 0.5 hr, by the 3 nmol 
dose at 1 hr, and by the 1 and 3 nmol doses at two hr (p<0.05). 
At 2 hr, mean intakes were 0 . 1 ± 0 . 1 ,  0 . 9±0 .5 ,  1.9---0.5 and 
2.5 ± 1.0 g for the 0, 0.5, 1 and 3 nmol doses respectively (n = 7). 
DISCUSSION 
We recently reported that central administration of a selective 
mu agonist stimulates saline intake in nondeprived rats (9). 
Because agonists at delta and kappa receptors are also thought to 
play a role in the mediation of taste preferences or the rewarding 
value of food, we measured the effects of two kappa and two delta 
agonists on the intake of a palatable salt solution. The delta 
agonists DTLET and DPDPE clearly caused preferential increases 
in the intake of 0.6% saline. That DTLET caused only a small 
increase in intake when only water was available suggests that the 
observed effects are not due simply to a generalized dipsogenesis. 
Furthermore, our recent report (8) that a mu and a delta agonist 
also stimulated saccharin intake indicates that the present results 
are not limited to the intake of saline solutions. These results, 
then, are consistent with the hypothesis that opioids are involved 
in the mediation of palatability (5,12). 
A clear role for kappa receptors in the control of saline intake 
was not demonstrated. The ineffectiveness of U-50,488H may 
possibly be attributed to subthreshold doses. The doses tested (10 
and 30 nmol) were selected because we recently found that higher 
doses (30 and 100 nmol) tended to decrease the intake of a 
palatable saccharin solution (8). The preferential kappa agonist 
DAFPHEDYN (3 nmol) caused a delayed increase in saline intake; 
doses of 1 and 3 nmol were also effective in stimulating food 
intake. That the effect on saline intake was not apparent until the 
second hourly measurement suggests the possibility that the 
increase was secondary to its diuretic effect (13). It is also possible 
that the effect of DAFPHEDYN is due to its action at mu 
receptors, as its affinity for mu receptors is only 2-fold less than 
that for kappa receptors (13). 
These results extend our previous research and indicate a role 
for central delta as well as mu receptors in the intake of or 
preference for palatable solutions. Additional testing with wider 
dose ranges of selective agonists will be necessary to determine 
whether kappa receptors may also be involved. 
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